0001493152-26-034815.txt : 20260727 0001493152-26-034815.hdr.sgml : 20260727 20260727163022 ACCESSION NUMBER: 0001493152-26-034815 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20260722 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260727 DATE AS OF CHANGE: 20260727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Glucotrack, Inc. CENTRAL INDEX KEY: 0001506983 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 980668934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41141 FILM NUMBER: 261206213 BUSINESS ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 BUSINESS PHONE: 972 (8) 675-7878 MAIL ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 FORMER COMPANY: FORMER CONFORMED NAME: GlucoTrack, Inc. DATE OF NAME CHANGE: 20220328 FORMER COMPANY: FORMER CONFORMED NAME: Integrity Applications, Inc. DATE OF NAME CHANGE: 20101203 8-K 1 form8-k.htm 8-K
false 0001506983 0001506983 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 22, 2026

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41141   98-0668934
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

301 Rte 17 North, Ste. 800, Rutherford, NJ   07070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 842-7715

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   GCTK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry Into a Material Definitive Agreement.

 

On July 22, 2026, Glucotrack, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor on September 12, 2025, in the original principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (the “First Exchange Agreement”), and further reduced by $988,000 pursuant to that certain exchange agreement, dated April 29, 2026, by and between the Company and the Investor (the “Second Exchange Agreement”) (as modified, the “Original Note”).

 

Pursuant to the Exchange Agreement, the Company and the Investor partitioned a new promissory note in the original principal amount of $900,000 (the “Partitioned Note”) from the Original Note. Following such partition, the outstanding balance of the Original Note was reduced by an amount equal to the initial outstanding balance of the Partitioned Note, and the Original Note otherwise remains in full force and effect in accordance with its terms.

 

Under the Exchange Agreement, the Company and the Investor further agreed that the Investor may, from time to time, exchange all or any portion of the Partitioned Note for shares of the Company’s common stock, par value $0.001 per share (the “Exchange Shares”). The number of Exchange Shares issuable in connection with each exchange is calculated by dividing the applicable tranche amount by the “Minimum Price,” which is equal to the lower of (A) the Nasdaq Official Closing Price of the common stock immediately preceding the delivery of the applicable exchange request, or (B) the arithmetic average of the five Nasdaq Official Closing Prices for the common stock immediately preceding the delivery of the applicable exchange request. Each exchange consists solely of the surrender and cancellation of the applicable portion of the Partitioned Note in exchange for the issuance of the Exchange Shares, with no cash or other consideration paid by the Investor.

 

The issuance of the Exchange Shares is subject to a beneficial ownership limitation, which generally restricts the Company from issuing shares to the Investor to the extent that such issuance would cause the Investor and its affiliates to beneficially own more than 9.99% of the Company’s outstanding common stock, calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. To the extent the limitation applies, the Exchange Shares may be issued in one or more tranches, and any portion of the Partitioned Note not exchanged as a result of the limitation will remain outstanding and exchangeable in accordance with the terms of the Exchange Agreement.

 

The Partitioned Note was issued in a private placement to the Investor pursuant to an exemption for transactions by an issuer not involving a public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Exchange Shares are being issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 3(a)(9) of the Securities Act, on the basis that (a) the Exchange Shares will be issued in exchange for other outstanding securities of the Company; (b) there will be no additional consideration delivered by the Investor in connection with the exchange; and (c) there will be no commissions or other remuneration paid by the Company in connection with the exchange.

 

The foregoing description of the Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the Exchange Agreement, a form which is filed herewith as Exhibit 10.1, and incorporated herein by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

To the extent required by Item 2.03 of Form 8-K, the information contained in Item 1.01 is hereby incorporated by reference into this Item 2.03 in its entirety.

 

Item 3.02. Unregistered Sales of Equity Securities

 

To the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 is hereby incorporated by reference into this Item 3.02 in its entirety.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Form of Exchange Agreement, dated July 22, 2026
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 27, 2026    
     
  GLUCOTRACK, INC.
     
  By: /s/ Erik Emerson
  Name: Erik Emerson
  Title: Chief Executive Officer

 

 

 

EX-10.1 2 ex10-1.htm EX-10.1

 

Exhibit 10.1

 

THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

EXCHANGE AGREEMENT

 

This Exchange Agreement (this “Agreement”) is entered into as of July 22, 2026 by and between                (“Lender”), and Glucotrack, Inc., a Delaware company (“Borrower”) and supersedes any prior agreement between the parties. Capitalized terms used in this Agreement without definition shall have the meanings given to them in the Original Note (defined below).

 

A. Borrower previously sold and issued to Lender that certain Promissory Note with an original issuance date of September 12, 2025 in the principal amount of $3,600,000 (the principal amount of which was subsequently reduced by $600,000, pursuant to that certain Exchange Agreement, dated April 13, 2026, by and between the Lender and the Borrower (the “First Exchange Agreement”), and further reduced by $988,000, pursuant to that certain Exchange Agreement, dated April 29, 2026, by and between the Lender and the Borrower (the “Second Exchange Agreement”), the “Original Note” together with all other documents entered into in conjunction therewith, the “Transaction Documents”).

 

B. Subject to the terms of this Agreement, Borrower and Lender desire to partition a new Promissory Note in the original principal amount of $900,000 (the “Partitioned Note”) from the Original Note and then cause the outstanding balance of the Original Note to be reduced by an amount equal to the initial outstanding balance of the Partitioned Note.

 

C. Borrower and Lender further desire to exchange (such exchange is referred to as the “Note Exchange”) the Partitioned Note for the delivery, from time to time, of shares of the Borrower’s common stock, par value $0.001 per share (the “Common Stock”), with the number of shares of Common Stock to be issued in connection with each Exchange Request (as defined below) to be calculated by dividing the applicable Tranche Amount (as defined below) by the Minimum Price (as defined below) (such shares of Common Stock, the “Exchange Shares”), with such Exchange Shares to be issued in one or more tranches upon request by Lender (each, an “Exchange Request” and each exchange, a “Tranche Exchange”), according to the terms and conditions of this Agreement. As used herein, “Minimum Price” means a price equal to the lower of (A) the Nasdaq Official Closing Price of the Common Stock immediately preceding the delivery of the applicable Exchange Request, or (B) the arithmetic average of the five (5) Nasdaq Official Closing Prices for the Common Stock immediately preceding the delivery of the applicable Exchange Request.

 

D. The Note Exchange will consist of Lender exchanging the Partitioned Note, in one or more Tranche Exchanges, for the Exchange Shares, which will be issued, from time to time, free of any restrictive securities legend pursuant to Rule 144. Upon the final Tranche Exchange in which the entire remaining outstanding balance of the Partitioned Note is exchanged, the Partitioned Note shall be deemed fully exchanged and extinguished. Other than the exchange of the Partitioned Note, no consideration of any kind whatsoever shall be given by Lender to Borrower in connection with this Agreement.

 

E. Lender and Borrower now desire to exchange the Partitioned Note for the Exchange Shares on the terms and conditions set forth herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1. Recitals and Definitions. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Agreement are true and accurate, are contractual in nature, and are hereby incorporated into and made a part of this Agreement.

 

2. Partition. Effective as of the date hereof, Borrower and Lender agree that the Partitioned Note is hereby partitioned from the Original Note. Following such partition of the Original Note, Borrower and Lender agree that the Original Note shall remain in full force and effect, provided that the outstanding balance of the Original Note shall be reduced by an amount equal to the initial outstanding balance of the Partitioned Note.

 

 

 

 

3. Issuance of Shares. Pursuant to the terms and conditions of this Agreement, Lender may, from time to time, deliver to Borrower a written request (each, an “Exchange Request”) specifying the principal amount of the Partitioned Note to be exchanged in such Tranche Exchange (the “Tranche Amount”) and the number of Exchange Shares to be issued in connection therewith. Upon receipt of an Exchange Request, Borrower shall deliver the applicable Exchange Shares to Lender within three (3) business days (or such other date as mutually agreed by the parties). The Exchange Shares shall be delivered via DWAC to Lender’s designated brokerage account. Upon delivery of the applicable Exchange Shares to Lender, the outstanding principal balance of the Partitioned Note shall be reduced by the applicable Tranche Amount, and Borrower’s obligations under the Partitioned Note with respect to such Tranche Amount shall be deemed fulfilled. Upon the final Tranche Exchange in which the entire remaining outstanding balance of the Partitioned Note is exchanged, the Partitioned Note shall be deemed fully exchanged and extinguished, and all of Borrower’s obligations thereunder shall terminate. Subject to the securities laws and regulations, Borrower agrees to provide all necessary cooperation or assistance that may be required to cause all Exchange Shares delivered hereunder to become Free Trading (the first date such occurs with respect to each tranche, the “Free Trading Date”). For purposes hereof, the term “Free Trading” means that (a) the Exchange Shares have been cleared and approved for public resale by the compliance departments of Lender’s brokerage firm and the clearing firm servicing such brokerage, and (b) such shares are held in the name of the clearing firm servicing Lender’s brokerage firm and have been deposited into such clearing firm’s account for the benefit of Lender. The Company shall issue the Exchange Shares in connection with each Tranche Exchange in one or more deliveries as necessary to comply with the Beneficial Ownership Limitation as set forth in Section 4 below. Any portion of a Tranche Amount not exchanged as a result of the Beneficial Ownership Limitation shall remain outstanding and shall be delivered as soon as practicable after compliance with the Beneficial Ownership Limitation permits, and any portion of the Partitioned Note not exchanged shall remain outstanding and exchangeable pursuant to the terms of this Agreement, subject to the Beneficial Ownership Limitation.

 

4. Beneficial Ownership Limitation. Notwithstanding anything provided herein to the contrary, the Company shall not issue Exchange Shares to Lender, and Lender shall not have the right to receive Exchange Shares pursuant to the Note Exchange, to the extent that after giving effect to such issuance, the Lender (together with Lender’s affiliates, and any other persons or entities acting as a group together with Lender or any of Lender’s affiliates (such persons or entities, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by Lender and its Attribution Parties shall include the number of shares of Common Stock issuable to Lender pursuant to the Note Exchange with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) the exchange of any remaining portion of the Partitioned Note that has not then been exchanged and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of Company (including for purposes of this paragraph, without limitation, any convertible notes, convertible stock, warrants, convertible loans or similar instruments) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by Lender or any of its Attribution Parties. Except as set forth in the preceding sentence, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, it being acknowledged by Lender that the Company is not representing to Lender that such calculation is in compliance with Section 13(d) of the Exchange Act and Lender is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 4 applies, the determination of whether, and to what extent, Exchange Shares may be issued to Lender pursuant to the Note Exchange (in relation to other securities owned by Lender together with any Attribution Parties) shall be made by Lender in its sole discretion. Any delivery instructions or notice provided by Lender to the Company in connection with the issuance of Exchange Shares shall be deemed to constitute Lender’s determination that the issuance of such Exchange Shares complies with the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 4, in determining the number of outstanding shares of Common Stock, Lender may rely on the number of outstanding shares of Common Stock as reflected in (A) Company’s most recent periodic or annual report filed with the SEC, as the case may be, (B) a more recent public announcement by Company or (C) a more recent written notice by Company or Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of Lender, Company shall within one trading day confirm orally and in writing to Lender the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Exchange Shares issued to Lender or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the applicable Exchange Shares pursuant to this Agreement. The provisions of this Section 4 shall be construed and implemented in a manner consistent with the terms hereof to give effect to the Beneficial Ownership Limitation and to correct any provision of this Section 4 (or any portion hereof) that may be defective or inconsistent with the intended Beneficial Ownership Limitation, or to make such changes or supplements as may be necessary or desirable to properly give effect thereto. Notwithstanding anything herein to the contrary, the Beneficial Ownership Limitation set forth in this Section 4 may not be amended or waived without the approval of the Company’s stockholders, to the extent required under applicable law or the rules of any national securities exchange on which the Company’s Common Stock is listed. The limitations contained in this Section 4 shall apply to any successor or permitted assign of Lender.

 

 

 

 

5. Closing. Each closing of a Tranche Exchange contemplated hereby (each, a “Closing”) along with the delivery of the applicable Exchange Shares to Lender shall occur on the date that is mutually agreed to by Borrower and Lender by means of the exchange by email of .pdf documents, but shall be deemed to have occurred at the offices of Grossman & Grossman P.C., 229 Broadway, Suite 1405. New York, NY 10007.

 

6. Holding Period, Tacking and Legal Opinion. Lender and Borrower agree that for the purposes of Rule 144 (“Rule 144”) of the Securities Act of 1933, as amended (the “Securities Act”), the holding period of the Partitioned Note and the Exchange Shares will include Lender’s holding period of the Original Note from September 12th, 2025, which date is the date that the Original Note was originally issued. Borrower agrees not to take a position contrary to this Section 6 in any document, statement, setting, or situation. Borrower agrees to take all action necessary to issue the Exchange Shares without restriction, and not containing any restrictive legend without the need for any action by Lender; provided that the applicable holding period has been met. In furtherance thereof, prior to the initial Closing, counsel to Lender may, in its sole discretion, provide an opinion covering all Tranche Exchanges that: (a) the Exchange Shares may be resold pursuant to Rule 144 without volume or manner-of-sale restrictions or current public information requirements; and (b) the transactions contemplated hereby and all other documents associated with this transaction comport with the requirements of Section 3(a)(9) of the Securities Act. Borrower represents that it is in full compliance with the tests and standards set forth in Rule 144(i)(2) as of the date of this Agreement. The Exchange Shares are being issued in substitution of and exchange for and not in satisfaction of the Partitioned Note. The Exchange Shares shall not constitute a novation or satisfaction and accord of the Partitioned Note. Borrower acknowledges and understands that the representations and agreements of Borrower in this Section 6 are a material inducement to Lender’s decision to consummate the transactions contemplated herein.

 

7. Representations, Warranties and Agreements of Borrower. In order to induce Lender to enter into this Agreement, Borrower, for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a) Borrower has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action, (b) no consent, approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement or the performance of any of the obligations of Borrower hereunder, (c) except as specifically set forth herein, nothing herein shall in any manner release, lessen, modify or otherwise affect Borrower’s obligations under the Original Note, (d) the issuance of the Exchange Shares is duly authorized by all necessary corporate action and the Exchange Shares are validly issued, fully paid and non-assessable, free and clear of all taxes, liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any kind, nature and description, (e) Borrower has not received any consideration in any form whatsoever for entering into this Agreement, other than the exchange of the Partitioned Note, and (f) Borrower has taken no action which would give rise to any claim by any person for a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related to this Agreement.

 

8. Representations, Warranties and Agreements of Lender. In order to induce Borrower to enter into this Agreement, Lender, for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a) Lender has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action, and (b) no consent, approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement or the performance of any of the obligations of Lender hereunder.

 

 
 

 

9. Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference. BORROWER HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

10. Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all signing parties had signed the same document. All counterparts shall be construed together and constitute the same instrument. The exchange of copies of this Agreement and of signature pages by facsimile transmission or other electronic transmission (including email) shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile transmission or other electronic transmission (including email) shall be deemed to be their original signatures for all purposes.

 

11. Attorneys’ Fees. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this Agreement, the prevailing party shall therefore be entitled to an additional award of the full amount of the attorneys’ fees and expenses paid by such prevailing party in connection with the arbitration, litigation and/or dispute without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. Nothing herein shall restrict or impair an arbitrator’s or a court’s power to award fees and expenses for frivolous or bad faith pleading.

 

12. No Reliance. Each party acknowledges and agrees that neither the other party nor any of such other party’s officers, directors, members, managers, equity holders, representatives or agents has made any representations or warranties to the party or any of its agents, representatives, officers, directors, or employees except as expressly set forth in this Agreement and the Transaction Documents and, in making its decision to enter into the transactions contemplated by this Agreement, the party is not relying on any representation, warranty, covenant or promise of the other party or such other party’s officers, directors, members, managers, equity holders, agents or representatives other than as set forth in this Agreement.

 

13. Severability. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect.

 

14. Entire Agreement. This Agreement, together with the Transaction Documents, and all other documents referred to herein, supersedes all other prior oral or written agreements between Borrower, Lender, its affiliates and persons acting on its behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Lender nor Borrower makes any representation, warranty, covenant or undertaking with respect to such matters.

 

 

 

 

15. Amendments. This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision of this Agreement may be waived except in writing signed by the party against whom such waiver is sought to be enforced.

 

16. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Lender hereunder may be assigned by Lender to a third party, including its financing sources, in whole or in part. Neither party shall assign this Agreement or any of its obligations herein without the prior written consent of the other party.

 

17. Continuing Enforceability; Conflict Between Documents. Except as otherwise modified by this Agreement, the Original Note and each of the other Transaction Documents shall remain in full force and effect, enforceable in accordance with all of its original terms and provisions. This Agreement shall not be effective or binding unless and until it is fully executed and delivered by Lender and Borrower. If there is any conflict between the terms of this Agreement, on the one hand, and the Original Note or any other Transaction Document, on the other hand, the terms of this Agreement shall prevail.

 

18. Time of Essence. Time is of the essence with respect to each and every provision of this Agreement.

 

19. Notices. Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under this Agreement to be given to Borrower or Lender shall be given as set forth in the “Notices” section of the Purchase Agreement.

 

20. Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

21. Conditional. The effectiveness of this Agreement is conditioned upon approval and consent of the bridge investors to the Borrower, and Borrower covenants to seek such consent promptly.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

 

BORROWER:

 

Glucotrack, Inc.

 

By:                
Name: Erik Emerson  
Title: Chief Executive Officer  
     
LENDER:  
   
   

 

 

[Signature Page to Exchange Agreement]

 

 

 

EX-101.SCH 3 gctk-20260722.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gctk-20260722_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 gctk-20260722_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover
Jul. 22, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 22, 2026
Entity File Number 001-41141
Entity Registrant Name GLUCOTRACK, INC.
Entity Central Index Key 0001506983
Entity Tax Identification Number 98-0668934
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 301 Rte 17 North
Entity Address, Address Line Two Ste. 800
Entity Address, City or Town Rutherford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07070
City Area Code (201)
Local Phone Number 842-7715
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol GCTK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00000001 - Document - Cover Sheet http://glucotrack.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm gctk-20260722.xsd gctk-20260722_lab.xml gctk-20260722_pre.xml http://xbrl.sec.gov/dei/2026 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GCTK", "nsuri": "http://glucotrack.com/20260722", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "gctk-20260722.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] }, "labelLink": { "local": [ "gctk-20260722_lab.xml" ] }, "presentationLink": { "local": [ "gctk-20260722_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2026": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2026": 23 }, "report": { "R1": { "role": "http://glucotrack.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2026-07-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-07-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentDescription", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AnnualInformationForm", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CountryRegion", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAccountingStandard", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAnnualReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodStartDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentRegistrationStatement", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine2", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine3", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCountry", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityExTransitionPeriod", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPrimarySicNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityVoluntaryFilers", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Extension", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NoTradingSymbolFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12gTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityReportingObligation", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SolicitingMaterial", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "WrittenCommunications", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-26-034815-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-26-034815-xbrl.zip M4$L#!!0 ( ,FC^USUD0ZM'B$ (NU * 97@Q,"TQ+FAT;>U=67/; MR+5^9Q7_0\#/?BOPO]MCT?C_>&; M[2?\7_CUB?R\O7.X]UF=C#_O#__^:)8FQ2NUM;DHU-C,=:X.](4Z3N=A$O"% M0)WHS,P>P8/PZ)%]KM!?B\=A;$Z35RK22:&SU^JF8[U6\S [-S*,W/R>3?/%Z^PD. M"#MRU%C+;>V=-\.O9V9BBGYO:W-C:_O)SIM+%_#??!A7 MSKM^2+PU=WQ*X_?#?F_XO[OO!P?OAFH71AY^.-H?C(=[ZOWP>#@Z4*,3-8*K M!WMP:7P(MWPX.CP>JT^C\7L%3ZOCX?]\'!T//PP/QB?J\*TZ&>Z.1X<'ZME: MN+[V/Q:#P:GJC![ABO;KU\]BQ0 _C[ XV^<261_&@;:^GD 2UI M^^,;2RG]WN#=\9 .??O)QS3W.5Z MQF*F>/@W4T\VG+]1DJ<)DJB:ZN- Z4;Q]=_O__=Y:-=-] M#9N5^=,,: +OXC)*BRR,O@1JE$0;<%7MZ3B\"#.MHG2^").E\L;92;,LO:B/ M1 /EY4)GN9["1N,CB\RDF0KM_O1[=J7%F5:+,"N,SC?4;K@P!9SMOV"K8,/F MN2ISVC5%&UUM_(4ISM*R4%,],XDI3)JH_"R,8W46GFL:2BM#D%9FR2,^[V#M-!JC<;1N/]Q>K&^\0!H]MO;.]]I(8,-98FLWUMD M^MRD90ZLDZ?QE"C-Y'F)])(J)FHXX+ J985(9SV49;.X8XT6RHZ:J0<>$RE M0@'T>)A$6DU#^!D8\T0O"CV?P$!;S)V_6*H!(DXBLT"R">=I"70(M__T+'BQ MN1EL;FZB./!N4M4]%VK MVI)B5F;P:&87 1P-JWCYM[_=?A7*7\33E__Y(DYTE";3+HE=7T;]*2L3B$Z\ M&V$)IYJ6RK0#4B:E/Z=I5.*@#?$.BX37_UXF$W8L?X8K.72/%K*SH4[*R>\Z N7%VD14%/!W73L%%6$BI0K1@B8TH$/A45)W M=.JA2N#]31$ETL9)J"Z)\M-+EA>@U.M$=60'!W)L$/*ZFL&;:OJ/7RC\!'0; M@K[EEY=%7L!U4*%J$L8D(&FAS6=A/1/=[WFB#(2KS!,$'=PFFT5Z&OZ\8N3F MW%?T?X\6LNOK88^NK1ZHZ%M;L;N6EZ#VW)_ (YF>Z2QC;0W:L$ZZ1$]69M?H MMHLX8(89"5=X@[VKFZPR4!3&41F3.ITLP3HPYX88 M#><2+A:QB<))K!5JG@@N#9A/.X8#/L9G/@#7SLLYB"@#;-IQ'Q]Q]^*:^LXN MH]\[H?OKRIB62Z.YY?)MK3T"$@#AJ.8IDANO!!R%!;PVD_V!V0MUKN$&HL'2 M.0_93U_9(V73IENR10^HKK-QY[K(%.Z,HC3C#?C@P-JH'.)N:K(U)^SF8E0"._& M:8[3Y',5SN"S@],ARC3SN9X:(*48O3<-PMT2DN4W^YQ'6$U*#?"@UG9X$F$& M1SS7A8D4>&E9>.K>/(/QU-HOZ\UY]GNUB>;(\]Y4U1W.=*5K[M%"]C;4^$R+ M<^Y.ZL* Z0U\E)N<;"!A<6%4>^9-/1$T14:3A6$>EJP:DB=@QPWE.;S9R:!. M/3,#7L9)(=@!CQ9 KP52=:ZC$NC>P/IC?0HSKKE&QR60XM;SYQOJ(\HOY@6T MK9J3A$7 -,B-Q)M@VU'99GH./A6N_!96%>%1,NPTZ+Z%P90)^ %G!QH=% MGNIS5KX\%T9R*ME>I/V>L[0[=&=#R#X OG@P##[[20@\-/8#N/,63V]O!XR&+Y-$T9YD.CG#1W M36BP_$*E;V"!##R3\:"3:%E!;VB^XXFC>QI] 2J+]=1)/X&?&9U&MV26QF!! MY:\>P)X^&.+8VE#;']\'84\5C1V^S.G:6 M"G3:.8.30D,TM"&7=::$,W"^ZD;R=M0;TET@5G6[Y$O76&- M7>C=C694Q_O8&F/#$PD<+4-DEXAA1$U;$( ?EIZ#D)XB0B/CW!A2= ;?78.* M[%"L&.D>+:2YA+\\?JS>&AU/7\'!G>K7\"!&RR)\0#U^+)EMVWNCW^SKK\MW M>('7)FD&E.VN[<2@#M06;$^>QF8*TQ@/=O:':G>XOW\TV-L;';S[^Z/-1_3W MR=%@U_XMKY31(N"U<)'#U.R_7H/C,2W.<'&;?^U:[?C8C@&>36&B,+;[#?.O M'T"L9_3$GGW"&[HB@/$>IO<=X__A"N"_L#4=NS3)=/CE\40#I\)L%K2U_LZ] MN#3IZZB^T7+9OO^H_D;O^)[@^?&1_9BD^6!X[!DIJY'$N?L]C'$+ (M&TU$M M5'M3S#*PVF(>=@/O@KWAA4K)J(O,%(5V2&V_=Q5 J]KX[+K*%V"HS986[ND* MCG7J44:1'82!NHLTI" M7K2X@?/7P?)6HDL=YK\.N_8P"A<7%O!'G!@ZGS#I M@%+=-K*"=!M\";!9S4!."M]%QBRJ][5GZVI2YB;1>0Y&RC)7:^!MT8Y0=)M3 M"]"0F9=HS,9+M@NF-C0@]O4Z076MMWH $LT2GCLWH=K[--BM9N1",.CRGR8< MMLC2+XP-(YA>$CA.VW,3++>YY*!E>%3D!]!5C![(&]B19\X;:"&YH2Y4QXN-S-QC/C;]0"B^A;X(8?@;@L@ MJB9^*!X2YE;,KMY"8AO>1WX)RBN#Q .4(A%Z*\I\\#6\8*&6Z5.,D.%8OODK MWF!J+5>:"[ JL$<(1!>EZ<+AE'![CB T[1+9MR $F53^*&%?IY0AP,%T'*9) MGQ5/5&LA01&E($'?(GO"\=%9K/&)8E(.\2,S*'J<>8MB*&PE 3&B_'[/2^SQ M1]T+ZXD!Z#=D"$POTEQ<9G17K#90W<.T@U&T%VOA>@V7L^$^SLV;8"Y/%.LP M$RH =H(=1Q*A*.2T&#:J] M@"6EN7$X +V[-K ;1P2B SXG.M$SXX5"6!3O2I8F

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end XML 15 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001506983 2026-07-22 2026-07-22 false 0001506983 8-K 2026-07-22 GLUCOTRACK, INC. DE 001-41141 98-0668934 301 Rte 17 North Ste. 800 Rutherford NJ 07070 (201) 842-7715 false false false false Common Stock GCTK NASDAQ false